表紙:医薬品有効成分のCDMO(医薬品製造開発受託)の世界市場:薬剤別、製品別、ワークフロー別、合成別、用途別、地域別の市場調査、予測(~2026年)、COVID-19の累積的な影響
市場調査レポート
商品コード
1027191

医薬品有効成分のCDMO(医薬品製造開発受託)の世界市場:薬剤別、製品別、ワークフロー別、合成別、用途別、地域別の市場調査、予測(~2026年)、COVID-19の累積的な影響

Active Pharmaceutical Ingredients CDMO Market Research Report by Drug, by Product, by Workflow, by Synthesis, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
医薬品有効成分のCDMO(医薬品製造開発受託)の世界市場:薬剤別、製品別、ワークフロー別、合成別、用途別、地域別の市場調査、予測(~2026年)、COVID-19の累積的な影響
出版日: 2021年09月07日
発行: 360iResearch LLP
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医薬品有効成分のCDMO(医薬品製造開発受託)の市場規模は、2020年に1,309億9,000万米ドル、2021年に1,424億7,000万米ドルとなり、年平均成長率(CAGR)9.09%で成長し、2026年までに2,208億8,000万米ドルとなると予想されています。

当レポートでは医薬品有効成分のCDMO(医薬品製造開発受託)の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、薬剤・製品・ワークフロー・合成・用途・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査のために考慮された年
  • 通貨と価格
  • 言語
  • 制限事項
  • 仮定
  • 利害関係者

第2章 調査手法

  • 定義:調査目的
  • 決定:調査デザイン
  • 準備:調査機器
  • 収集:データソース
  • 分析:データの解釈
  • 策定:データ検証
  • 公開:調査レポート
  • 繰り返し:レポートの更新

第3章 エグゼクティブサマリー

  • 市場の見通し
  • 薬剤の見通し
  • 製品の見通し
  • ワークフローの見通し
  • 合成の見通し
  • 用途の見通し
  • 地域の見通し
  • 競合他社の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズのファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 薬剤別

  • ジェネリック
  • 革新的

第7章 製品別

  • 抗体薬物複合体(ADC)
  • 超強力有効成分(HP-API)
  • 従来型有効成分(従来型API)

第8章 ワークフロー別

  • クリニカル
  • 商業

第9章 合成別

  • バイオテクノロジー
  • 合成

第10章 用途別

  • 心血管
  • 糖尿病
  • 緑内障
  • ホルモン
  • 腫瘍学

第11章 南北アメリカ

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • タイ

第13章 欧州、中東・アフリカ

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • キープレーヤー別市場シェア分析
  • 競合シナリオ
    • 合併と買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第15章 企業のユーザビリティプロファイル

  • AbbVie, Inc.
  • Albemarle Corporation
  • Boehringer Ingelheim
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cambrex
  • Catalent
  • Cipla, Inc.
  • Corden Pharma.
  • Lonza
  • Merck & Co., Inc.
  • Piramal Pharma Solutions
  • ReciPharm
  • Samsung Biologics
  • Siegfried
  • Teva Pharmaceutical Industries Ltd.
  • ThermoFisher Pantheon

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2020 (USD BILLION)
  • FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2020 (USD BILLION)
  • FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2020 (USD BILLION)
  • FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2020 (USD BILLION)
  • FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: MARKET DYNAMICS
  • FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2020 VS 2026 (%)
  • FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2020 VS 2026 (USD BILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2026
  • FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, 2018-2026 (USD BILLION)
  • FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, 2018-2026 (USD BILLION)
  • FIGURE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2020 VS 2026 (%)
  • FIGURE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2020 VS 2026 (USD BILLION)
  • FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2026
  • FIGURE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE (ADC), 2018-2026 (USD BILLION)
  • FIGURE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE (ADC), BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT (HP-API), 2018-2026 (USD BILLION)
  • FIGURE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT (HP-API), BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT (TRADITIONAL API), 2018-2026 (USD BILLION)
  • FIGURE 26. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT (TRADITIONAL API), BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 27. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2020 VS 2026 (%)
  • FIGURE 28. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2020 VS 2026 (USD BILLION)
  • FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2026
  • FIGURE 30. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, 2018-2026 (USD BILLION)
  • FIGURE 31. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 32. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, 2018-2026 (USD BILLION)
  • FIGURE 33. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 34. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2020 VS 2026 (%)
  • FIGURE 35. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2020 VS 2026 (USD BILLION)
  • FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2026
  • FIGURE 37. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, 2018-2026 (USD BILLION)
  • FIGURE 38. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 39. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, 2018-2026 (USD BILLION)
  • FIGURE 40. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 41. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
  • FIGURE 42. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD BILLION)
  • FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2026
  • FIGURE 44. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, 2018-2026 (USD BILLION)
  • FIGURE 45. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 46. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, 2018-2026 (USD BILLION)
  • FIGURE 47. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 48. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, 2018-2026 (USD BILLION)
  • FIGURE 49. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 50. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, 2018-2026 (USD BILLION)
  • FIGURE 51. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 52. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, 2018-2026 (USD BILLION)
  • FIGURE 53. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2020 VS 2026 (USD BILLION)
  • FIGURE 54. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 55. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 56. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 57. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 58. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 59. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 60. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 61. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 62. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 63. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 64. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 65. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 66. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 67. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 68. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 69. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 70. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 71. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 72. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 73. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 74. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 75. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 76. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 77. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 78. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 79. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 80. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 81. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 82. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • FIGURE 83. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: FPNV POSITIONING MATRIX
  • FIGURE 84. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 85. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
  • TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2026 (USD BILLION)
  • TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE (ADC), BY REGION, 2018-2026 (USD BILLION)
  • TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT (HP-API), BY REGION, 2018-2026 (USD BILLION)
  • TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT (TRADITIONAL API), BY REGION, 2018-2026 (USD BILLION)
  • TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2026 (USD BILLION)
  • TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2026 (USD BILLION)
  • TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
  • TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2026 (USD BILLION)
  • TABLE 23. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 24. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 25. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 26. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 27. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 28. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 29. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 30. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 31. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 32. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 33. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 34. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 35. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 36. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 37. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 38. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 39. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 40. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 41. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 42. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 43. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 44. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 45. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 46. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 47. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 48. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 49. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 50. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 51. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2026 (USD BILLION)
  • TABLE 52. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: SCORES
  • TABLE 53. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: BUSINESS STRATEGY
  • TABLE 54. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: PRODUCT SATISFACTION
  • TABLE 55. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: RANKING
  • TABLE 56. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 57. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: MERGER & ACQUISITION
  • TABLE 58. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 59. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 60. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: INVESTMENT & FUNDING
  • TABLE 61. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 62. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: LICENSE & PRICING
目次
Product Code: MRR-575EAC9DD1CB

The Global Active Pharmaceutical Ingredients CDMO Market size was estimated at USD 130.99 Billion in 2020 and expected to reach USD 142.47 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 9.09% to reach USD 220.88 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Active Pharmaceutical Ingredients CDMO to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Drug, the Active Pharmaceutical Ingredients CDMO Market was studied across Generics and Innovative.
  • Based on Product, the Active Pharmaceutical Ingredients CDMO Market was studied across Antibody Drug Conjugate (ADC), Highly Potent Active Pharmaceutical Ingredient (HP-API), and Traditional Active Pharmaceutical Ingredient (Traditional API).
  • Based on Workflow, the Active Pharmaceutical Ingredients CDMO Market was studied across Clinical and Commercial.
  • Based on Synthesis, the Active Pharmaceutical Ingredients CDMO Market was studied across Biotech and Synthetic.
  • Based on Application, the Active Pharmaceutical Ingredients CDMO Market was studied across Cardiovascular, Diabetes, Glaucoma, Hormonal, and Oncology.
  • Based on Region, the Active Pharmaceutical Ingredients CDMO Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Active Pharmaceutical Ingredients CDMO Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Active Pharmaceutical Ingredients CDMO Market, including AbbVie, Inc., Albemarle Corporation, Boehringer Ingelheim, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cambrex, Catalent, Cipla, Inc., Corden Pharma., Lonza, Merck & Co., Inc., Piramal Pharma Solutions, ReciPharm, Samsung Biologics, Siegfried, Teva Pharmaceutical Industries Ltd., and ThermoFisher Pantheon.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Active Pharmaceutical Ingredients CDMO Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Active Pharmaceutical Ingredients CDMO Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Active Pharmaceutical Ingredients CDMO Market?
  • 4. What is the competitive strategic window for opportunities in the Global Active Pharmaceutical Ingredients CDMO Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Active Pharmaceutical Ingredients CDMO Market?
  • 6. What is the market share of the leading vendors in the Global Active Pharmaceutical Ingredients CDMO Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Active Pharmaceutical Ingredients CDMO Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Outlook
  • 3.4. Product Outlook
  • 3.5. Workflow Outlook
  • 3.6. Synthesis Outlook
  • 3.7. Application Outlook
  • 3.8. Region Outlook
  • 3.9. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing pharmaceutical R&D investment
      • 5.1.1.2. Rising demand for generic drugs and biologic innovation
      • 5.1.1.3. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
    • 5.1.2. Restraints
      • 5.1.2.1. Compliance issues while outsourcing
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding consumption of biopharmaceuticals
      • 5.1.3.2. Rising prevalence of cancer and increasing sophistication in oncology drug research
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Active Pharmaceutical Ingredients CDMO Market, by Drug

  • 6.1. Introduction
  • 6.2. Generics
  • 6.3. Innovative

7. Active Pharmaceutical Ingredients CDMO Market, by Product

  • 7.1. Introduction
  • 7.2. Antibody Drug Conjugate (ADC)
  • 7.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
  • 7.4. Traditional Active Pharmaceutical Ingredient (Traditional API)

8. Active Pharmaceutical Ingredients CDMO Market, by Workflow

  • 8.1. Introduction
  • 8.2. Clinical
  • 8.3. Commercial

9. Active Pharmaceutical Ingredients CDMO Market, by Synthesis

  • 9.1. Introduction
  • 9.2. Biotech
  • 9.3. Synthetic

10. Active Pharmaceutical Ingredients CDMO Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular
  • 10.3. Diabetes
  • 10.4. Glaucoma
  • 10.5. Hormonal
  • 10.6. Oncology

11. Americas Active Pharmaceutical Ingredients CDMO Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Thailand

13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market

  • 13.1. Introduction
  • 13.2. France
  • 13.3. Germany
  • 13.4. Italy
  • 13.5. Netherlands
  • 13.6. Qatar
  • 13.7. Russia
  • 13.8. Saudi Arabia
  • 13.9. South Africa
  • 13.10. Spain
  • 13.11. United Arab Emirates
  • 13.12. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
    • 14.1.1. Quadrants
    • 14.1.2. Business Strategy
    • 14.1.3. Product Satisfaction
  • 14.2. Market Ranking Analysis
  • 14.3. Market Share Analysis, By Key Player
  • 14.4. Competitive Scenario
    • 14.4.1. Merger & Acquisition
    • 14.4.2. Agreement, Collaboration, & Partnership
    • 14.4.3. New Product Launch & Enhancement
    • 14.4.4. Investment & Funding
    • 14.4.5. Award, Recognition, & Expansion

15. Company Usability Profiles

  • 15.1. AbbVie, Inc.
  • 15.2. Albemarle Corporation
  • 15.3. Boehringer Ingelheim
  • 15.4. Boehringer Ingelheim International GmbH
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. Cambrex
  • 15.7. Catalent
  • 15.8. Cipla, Inc.
  • 15.9. Corden Pharma.
  • 15.10. Lonza
  • 15.11. Merck & Co., Inc.
  • 15.12. Piramal Pharma Solutions
  • 15.13. ReciPharm
  • 15.14. Samsung Biologics
  • 15.15. Siegfried
  • 15.16. Teva Pharmaceutical Industries Ltd.
  • 15.17. ThermoFisher Pantheon

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing